Evidence map›Paper›PMID 37573454›Full record

ArticleNPJ vaccines2023

Modified influenza M1

Josien Lanfermeijer, Koen van de Ven, Harry van Dijken, Marion Hendriks, Cami M P Talavera Ormeño, Femke de Heij, Paul Roholl, José A M Borghans, Debbie van Baarle, Jørgen de Jonge

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Josien LanfermeijerCenter for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands.
Koen van de VenCenter for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands.ORCID http://orcid.org/0000-0001-7549-5683
Harry van DijkenCenter for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands.
Marion HendriksCenter for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands.
Cami M P Talavera OrmeñoDepartment of Cell and Chemical Biology, Leiden University Medical Centre, Leiden, The Netherlands.ORCID http://orcid.org/0000-0001-5502-2985
Femke de HeijCenter for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands.
Paul RohollMicroscope Consultancy, Weesp, Netherlands.
José A M BorghansCenter for Translational Immunology, University Medical Center Utrecht, Utrecht, the Netherlands.
Debbie van BaarleCenter for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands.
Jørgen de JongeCenter for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands. Jorgen.de.jonge@rivm.nl.ORCID http://orcid.org/0000-0003-3167-2435
National Institute for Public Health and the Environment · NLUniversity Medical Center Utrecht · NLLeiden University Medical Center · NLUniversity Medical Center Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CD8 + T cells are promising targets for vaccination against influenza A virus (IAV) infection. Their induction via peptide vaccination is not trivial, because peptides are weakly immunogenic. One strategy to overcome this is by vaccination with chemically enhanced altered peptide ligands (CPLs), which have improved MHC-binding and immunogenicity. It remains unknown how peptide-modification affects the resulting immune response. We studied the effect of CPLs derived from the influenza M1

Identifiers

PMID37573454
PMCPMC10423225
OpenAlexW4385781764

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.